IL312357A - Piperidinylpyrazine-carboxamide compounds for the treatment and prevention of cancer and to restore BTK - Google Patents
Piperidinylpyrazine-carboxamide compounds for the treatment and prevention of cancer and to restore BTKInfo
- Publication number
- IL312357A IL312357A IL312357A IL31235724A IL312357A IL 312357 A IL312357 A IL 312357A IL 312357 A IL312357 A IL 312357A IL 31235724 A IL31235724 A IL 31235724A IL 312357 A IL312357 A IL 312357A
- Authority
- IL
- Israel
- Prior art keywords
- piperidinylpyrazine
- treating
- preventing cancer
- carboxamide compounds
- btk
- Prior art date
Links
- LYWGPLOCAIBMLS-UHFFFAOYSA-N 3-piperidin-1-ylpyrazine-2-carboxamide Chemical class NC(=O)C1=NC=CN=C1N1CCCCC1 LYWGPLOCAIBMLS-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000000593 degrading effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263081P | 2021-10-26 | 2021-10-26 | |
| US202263391671P | 2022-07-22 | 2022-07-22 | |
| PCT/US2022/047767 WO2023076303A1 (en) | 2021-10-26 | 2022-10-25 | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312357A true IL312357A (en) | 2024-06-01 |
Family
ID=84361163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312357A IL312357A (en) | 2021-10-26 | 2022-10-25 | Piperidinylpyrazine-carboxamide compounds for the treatment and prevention of cancer and to restore BTK |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12377106B2 (enExample) |
| EP (1) | EP4422630A1 (enExample) |
| JP (1) | JP2024542984A (enExample) |
| KR (1) | KR20240090898A (enExample) |
| AU (1) | AU2022379494A1 (enExample) |
| CA (1) | CA3236073A1 (enExample) |
| IL (1) | IL312357A (enExample) |
| MX (1) | MX2024004899A (enExample) |
| WO (1) | WO2023076303A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113412259B (zh) | 2018-10-15 | 2024-07-16 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| MX2022006672A (es) | 2019-12-04 | 2022-08-08 | Nurix Therapeutics Inc | Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina. |
| WO2023076303A1 (en) | 2021-10-26 | 2023-05-04 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099388A2 (en) | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| DK2069381T3 (da) | 2006-09-13 | 2016-03-14 | Univ Columbia | Midler og fremgangsmåder til udløsning af anti-tumorimmunrespons |
| AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| DK2242749T3 (da) | 2008-02-05 | 2013-06-17 | Hoffmann La Roche | Nye pyridinoner og pyridazinoner |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| KR101862327B1 (ko) | 2010-05-07 | 2018-05-29 | 질레드 코네티컷 인코포레이티드 | 피리돈 및 아자-피리돈 화합물 및 사용 방법 |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US8669251B2 (en) | 2011-11-03 | 2014-03-11 | Genentech, Inc. | 8-fluorophthalazin-1(2H)-one compounds |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| CA2881761A1 (en) | 2012-09-13 | 2014-03-20 | Christine E. Brotherton-Pleiss | Inhibitors of bruton's tyrosine kinase |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| EP3077388A1 (en) | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MA42623A (fr) | 2015-06-02 | 2018-06-20 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| PL3532607T3 (pl) | 2016-10-26 | 2024-07-01 | Iovance Biotherapeutics, Inc. | Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| AU2017363252B2 (en) | 2016-11-22 | 2021-08-19 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3743063A4 (en) | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| JP2021512059A (ja) | 2018-01-29 | 2021-05-13 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
| TW202513579A (zh) * | 2018-06-19 | 2025-04-01 | 美商百歐恩泰美國公司 | 新抗原及其用途 |
| CN113412259B (zh) * | 2018-10-15 | 2024-07-16 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| AU2020272937B2 (en) | 2019-04-09 | 2024-09-26 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| JP7587528B2 (ja) | 2019-05-17 | 2024-11-20 | ニューリックス セラピューティクス，インコーポレイテッド | Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用 |
| CA3144450A1 (en) | 2019-06-26 | 2020-12-30 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| AU2020320195A1 (en) | 2019-07-30 | 2022-03-10 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition |
| US12121540B2 (en) | 2019-09-24 | 2024-10-22 | Nurix Therapeutics, Inc. | CBL inhibitors and compositions for use in adoptive cell therapy |
| WO2021091575A1 (en) | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| MX2022006672A (es) * | 2019-12-04 | 2022-08-08 | Nurix Therapeutics Inc | Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina. |
| AU2022310182A1 (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with diminished imid activity |
| EP4373493A1 (en) * | 2021-07-23 | 2024-05-29 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
| WO2023076303A1 (en) | 2021-10-26 | 2023-05-04 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
-
2022
- 2022-10-25 WO PCT/US2022/047767 patent/WO2023076303A1/en not_active Ceased
- 2022-10-25 AU AU2022379494A patent/AU2022379494A1/en active Pending
- 2022-10-25 US US18/049,547 patent/US12377106B2/en active Active
- 2022-10-25 KR KR1020247017265A patent/KR20240090898A/ko active Pending
- 2022-10-25 CA CA3236073A patent/CA3236073A1/en active Pending
- 2022-10-25 MX MX2024004899A patent/MX2024004899A/es unknown
- 2022-10-25 JP JP2024525065A patent/JP2024542984A/ja active Pending
- 2022-10-25 IL IL312357A patent/IL312357A/en unknown
- 2022-10-25 EP EP22809599.8A patent/EP4422630A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240090898A (ko) | 2024-06-21 |
| MX2024004899A (es) | 2024-05-24 |
| WO2023076303A1 (en) | 2023-05-04 |
| US12377106B2 (en) | 2025-08-05 |
| US20230149416A1 (en) | 2023-05-18 |
| JP2024542984A (ja) | 2024-11-19 |
| CA3236073A1 (en) | 2023-05-04 |
| EP4422630A1 (en) | 2024-09-04 |
| AU2022379494A1 (en) | 2024-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304275A (en) | Cancer treatment methods | |
| IL312680A (en) | Cancer treatment methods | |
| PT4181920T (pt) | Inibidor de kat6 e combinações para o tratamento do cancro da mama | |
| HUE069249T2 (hu) | Kombinációs terápia rák kezelésére | |
| IL320332A (en) | Cancer treatment methods | |
| IL307964A (en) | Combined treatment for cancer | |
| IL319513A (en) | Compounds for cancer treatment | |
| IL315800A (en) | Preparations and methods for the treatment of cancer | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| IL316016A (en) | Combined treatment for cancer | |
| IL316017A (en) | Combined treatment for cancer | |
| IL309120A (en) | Methods and compositions for the treatment of cancer | |
| IL309071A (en) | Methods and compositions for the treatment of cancer | |
| IL305974A (en) | Pharmaceutical combinations for cancer treatment | |
| IL288178A (en) | Combined gmci and ddri treatment for cancer | |
| AU2023419820A1 (en) | Compounds and methods for treating cancer | |
| IL317573A (en) | Combination therapy for cancer treatment | |
| IL316019A (en) | Combined treatment for cancer | |
| KR102349013B9 (ko) | 멜라토닌을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
| GB202101728D0 (en) | Compounds and their use treating cancer | |
| IL312846A (en) | Methods and preparations for the treatment of cancer | |
| EP4337328A4 (en) | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER | |
| IL286680A (en) | A drug to treat cancer | |
| EP4226945A4 (en) | MEDICINES FOR THE TREATMENT OF CANCER | |
| KR102371980B9 (ko) | 췌장암 예방 또는 치료용 조성물 |